*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Tenofovir Alafenamide (TAF) is a prodrug of tenofovir designed for enhanced intracellular delivery. Its <strong>core synthesis</strong> involves phosphoramidate coupling to improve stability and reduce systemic exposure. Molecular formula: C<sub>24</sub>H<sub>31</sub>N<sub>6</sub>O<sub>7</sub>P; CAS No.: 1350783-64-6.</p>
<h3>Application</h3>
<ul>
<li><strong>Viral Hepatitis B:</strong> First-line treatment for chronic HBV infection with optimized dosing.</li>
<li><strong>HIV Management:</strong> Component in combination antiretroviral therapy (cART) regimens.</li>
<li><strong>Pharmaceutical Manufacturing:</strong> API production for fixed-dose combination tablets.</li>
</ul>
<h3>Precautions</h3>
<p>Contraindicated in severe renal impairment without dose adjustment. Requires storage below 30°C in dry conditions. Strict adherence to pharmacovigilance protocols regarding bone mineral density changes is mandatory during clinical use.</p>